ALKBH5-mediated m6A modification of circCCDC134 facilitates cervical cancer metastasis by enhancing HIF1A transcription

Leilei Liang, Yunshu Zhu, Jian Li, Jia Zeng and Lingying Wu*

Abstract

Background: Metastasis is the main cause of mortality in cervical cancer (CC). Circular RNAs (circRNAs) have been demonstrated to play a crucial role in carcinoma biology. However, the expression and function of circRNAs in cervical cancer metastasis are still unclear.

Methods: In the present study, we identified a circRNA with an N6-methyladenosine (m6A) modification, circCCDC134, whose expression was increased in CC tissues by circRNA-Seq and qPCR. CircCCDC134 upregulation in CC was fine-tuned by ALKBH5-mediated m6A modification, which enhanced its stability in a YTHDF2-dependent manner. The functional experiments illustrated that circCCDC134 enhanced tumour proliferation and metastasis in vitro and in vivo. For the comprehensive identification of RNA-binding proteins, circRNA pull-down and mass spectrometry (ChIRP-MS), chromatin immunoprecipitation-seq (Chip-seq), RNA binding protein immunoprecipitation (RIP) and luciferase reporter assays were used to perform mechanistic investigations.

Results: The results revealed that circCCDC134 recruited p65 in the nucleus and acted as a miR-503-5p sponge to regulate the expression of MYB in the cytoplasm, ultimately stimulating HIF1A transcription and facilitating CC growth and metastasis. Conclusion: These findings indicate that circCCDC134 is an important therapeutic target and provide new regulatory model insights for exploring the carcinogenic mechanism of circCCDC134 in CC.

Keywords: Cervical cancer metastasis, circCCDC134, m6A methylation, p65, miR-503-5p

Background

Cervical cancer (CC) remains the fourth most common gynaecological malignancy worldwide, with approximately 604,000 new cases and 342,000 deaths each year [1]. The clinical outcome of early-stage cervical cancer has improved due to surgery, radiotherapy, and chemotherapy. However, the prognosis of recurrent and metastatic CC is still unsatisfactory, and it is necessary to identify new therapeutic targets to improve the antitumor effect in advanced cervical cancer.

Circular RNAs (circRNAs), as a special type of noncoding RNA, have a closed circular structure without 5′ and 3′ ends and are not degraded by RNA exoenzymes [2]. Based on this circular structure, circRNAs are more conserved and stable. Current research has shown that circRNAs have a high degree of tissue specificity and play an essential role in regulating tumorigenesis and progression [3]. Recent studies have revealed that the known functions of circRNAs include roles as transcriptional regulators, microRNA (miRNA) sponges, RNA-binding protein (RBP) decoys, and translation into proteins [2, 4, 5]. The circ102049-miR-761/miR-192-3p-FRAS1 axis is an anti-metastatic target in colorectal cancer [6]; circASAP1 is a key regulator of hepatocellular carcinoma metastasis that acts on miR-326/miR-532-5p-MAPK1/CSF-1 signalling
cervical cancer (ME180, CaSki, SiHA, and HCC94) lines were transfected with these siRNAs with siRNA-mate (GenePharma, Shanghai, China). Forty-eight hours post-infection, the cells were collected and processed for various assays. Lentivirus plasmids of shRNA were constructed by Genechem Company (Shanghai, China) and packaged using pMD2. G and psPAX2 (Addgene, Cambridge, MA) into the cell. For circCCDC134 overexpression (EX-circCCDC134), the sequence was cloned into the pLCDH-cir vector and packaged using pMD2. G and psPAX2. Information regarding the sequences is shown in Supplementary Table 2.

Quantitative real-time PCR (qRT–PCR) and immunohistochemistry

The total RNA extraction was performed using RNAeasy Isolation Reagent (No. RC112-01, Vazyme, China). qRT–PCR was performed using a HiScript III 1st Strand cDNA Synthesis Kit (No. R312-01, Vazyme, China) and ChamQ™ Universal SYBR® qPCR Master Mix (No. Q712-02, Vazyme, China) according to the manufacturer’s instructions. For immunohistochemistry, the expression levels of ALKBH5 and HIF1A were measured by immunohistochemical staining with antibodies against ALKBH5 (1:200) (ab195377, Abcam, UK) and HIF1A (1:200) (ab51608, Abcam, UK). The total RNA extraction, qRT–PCR analysis and immunohistochemistry were performed as previously described [15]. Information regarding the sequences is shown in Supplementary Table 2.

Actinomycin D and RNase R treatment

ME180 cells reached 70% confluence in six-well plates, and the cells were treated with 5μg/ml actinomycin D and collected at the designated time point. For the RNase R treatment, the total RNA and 2.5U/μg RNase R (ab286929, Abcam, UK) were incubated at 37°C for 20min. After the actinomycin D or RNase R treatment, the RNA expression levels of circCCDC134 and CCDC134 mRNA were analysed by qRT–PCR.

RNA fluorescence in situ hybridization (FISH) and RNA fractionation assays

RNA-FISH was conducted using a Ribo fluorescence in situ hybridization kit (C10910, RiboBio, China) in accordance with the manufacturer’s directions. circCCDC134 and hsa-miR-503-5p FISH probes were
designed and synthesized by RiboBio. In brief, the cells were seeded, fixed with 4% paraformaldehyde and incubated with a hybridized 5 mM probe at 37 °C overnight. All images were visualized and obtained under a confocal microscope (Philips).

In total, $1 \times 10^6$ cells were used for the RNA fractionation assays. RNA from the nucleus and cytoplasm was separated by a Cytoplasmic & Nuclear RNA Purification Kit (Norgen Biotek Corp, Canada) following the manufacturer’s instructions.

**RNA pulldown and RNA immunoprecipitation assays**

The circRNA pull-down assay was performed with a TRAP (tagged RNA affinity purification) kit (BersinBio, Guangzhou, China) according to the manufacturer’s instructions. In brief, we constructed a plasmid with circCCDC134 and MS2. We also constructed a plasmid with MS2-CP-Flag, which was fused with a mCherry tag (MS2-CP-FlagmCherry). CC cells were transfected with these two plasmids, and circCCDC134 was precipitated by pulldown using anti-Flag antibodies. Lysates derived from cells without the MS2 tagging system were used as controls. The cell lysates were incubated with Protein A/G beads overnight at 4 °C. Then, the RNA and bound proteins were eluted; RNA was analysed by qPCR; and the bound proteins were analysed by label-free mass spectrometry (MS) and Western blot assays.

The RNA immunoprecipitation (RIP) assay was performed with a RIP kit (BersinBio, Guangzhou, China) according to the manufacturer’s instructions. In brief, magnetic beads were incubated with 10 μg of antibodies against ALKBH5 (16837-1-AP, Proteintech, China), YTHDF2 (ab220163, Abcam, Cambridge, USA), p65 (ab16502, Abcam, Cambridge, USA) and normal IgG (Millipore, Massachusetts, USA) overnight at 4 °C. Methylated RNA immunoprecipitation was performed with a MeRIP kit (BersinBio, Guangzhou, China) according to the manufacturer’s instructions, and an anti-N6-methyladenosine (m6A) antibody (ab286164, Abcam, Cambridge, USA) was used for MeRIP. The Western blot and RIP assays were performed as previously described [16].

**Chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq) and CUT&Tag**

The ChIP assay was performed with a CUT&Tag Assay Kit (No. TD903-01, Vazyme, China) according to the manufacturer’s instructions. In brief, chromatin solution was added to 10 μg of NF-κB, p65 (8242S, Cell Signaling Technology, China) or Myb antibodies (ab177510, Abcam) and incubated overnight at 4 °C with slow rotation. The ChIP assays were performed as previously described [17].

**Animal studies**

The animal experiments were approved by the Animal Center of the Institute of National Cancer Center/Cancer Hospital, CAMS & PUMC and followed the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Four-week-old female nude mice (BALB/c-nu, HFK Bioscience, Beijing, China) were subcutaneously injected with ME180 cells stably expressing shRNA circCCDC134 or an empty vector. The tumour size was measured every 7 days. At the end of the experiment (after 4 weeks), the mice were euthanized by an intraperitoneal injection of 100 mg/kg pentobarbital sodium (Sigma, St. Louis, MO, USA), and the xenograft tumours were resected and weighed. To measure cell metastasis in vivo, a lung metastasis model was used. Briefly, $1 \times 10^6$ ME180 cells (shRNA circCCDC134 or empty vector) in 0.1 mL of phosphate-buffered saline were injected into the tail vein of nude mice. After 4 weeks of feeding, the animals were euthanized, and the lung tissues were removed for further processing.

**Statistical analysis**

All statistical analyses were performed with GraphPad Prism v. 8.01 (GraphPad Software, La Jolla, CA, USA). Student’s t-test was used to compare values between the test and control groups. $P$-values < 0.05 indicated statistical significance.

**Data availability**

The data generated in this study are available upon request from the corresponding author.

**Results**

**CircCCDC134 was significantly upregulated in CC tissues**

circRNA-Seq was used to analyse the dysregulated circRNA expression between 4 pericarcinomatous and 4 CC tissues, which was supported by GENESEED (Guangzhou, China). We found hundreds of circRNAs that varied between the CC tissue and adjacent normal tissue. We detected 21 upregulated circRNAs with a 2-fold change ($p < 0.05$) (Fig. 1A and B), and one of the new molecules that attracted our attention was circCCDC134 (hsa_circ_0008806, 580 bp). Next, the characteristics of circCCDC134 in CC were analysed. Primers for circCCDC134 were designed for the qRT–PCR experiments (Supplementary Fig. 1A and B). The circular structure of circCCDC134 was confirmed by amplification with divergent primers, followed by Sanger sequencing, which showed that circCCDC134 was generated from exon 2 to exon 6 of the CCDC134 gene through back splicing (Fig. 1C). Oligo (dT) and random primers were employed to identify whether circCCDC134 contains poly-A tails.
by qRT–PCR. If the expression of the target gene cannot be detected in the reverse transcribed cDNA of Oligo (dT), the RNA has no poly-A tail and is a circular RNA. We verified the circular feature of circCCDC134 and conducted qRT–PCR using oligo (dT) and random primers, and the results suggested that compared with random primers, circCCDC134 expression was noticeably reduced, while CCDC134 expression did not change when using the oligo (dT) primers, revealing that circCCDC134 contained no poly-A tail (Fig. 1D). To further detect the features of circCCDC134, both circCCDC134 and the linear mRNA CCDC134 were treated with RNase R and the transcription inhibitor actinomycin D. Ribonuclease R is only able to degrade linear RNA but does not affect circRNA. The results showed that circCCDC134 was more resistant to both RNase R (Fig. 1E and F) and actinomycin D (Fig. 1G), suggesting that circCCDC134 was more stable than linear CCDC134. For the localization of circRNA, FISH and RNA fractionation assays were further performed. The cytoplasmic and nuclear RNA of ME180 and SiHA cell lines were separated and extracted, and qRT–PCR was performed to determine circCCDC134 expression in the cytoplasm and nucleus by RNA fractionation assays. J and K The qRT–PCR results revealed circCCDC134 overexpression in 24 tumour and 10 metastatic tissues and CC cells.
among the CC cells, the expression of circCCDC134 was higher in the ME180 and SiHA cells and lower in the HCC94 cells than in the other CC cells (Fig. 1K).

**m6A modification of circCCDC134 enhanced its stability**

First, we explored the potential mechanism of circCCDC134 upregulation in CC. Previous research has shown that m6A modification plays a pivotal role in posttranscriptional regulation and the biogenesis of circRNAs. We analysed the m6A modification of circCCDC134 using circPrimer (Fig. 2A) and the SRAMP prediction server (http://www.cuilab.cn/sramp/) (Fig. 2B), and there were many m6A modification sites of circCCDC134. The motif analysis of the circCCDC134 methylation site based on the very high confidence of SRAMP is shown in Fig. 2C.

To explore this further, we first performed RNA pull-down assays and a mass spectrometry analysis (ChIRP-MS) to screen circCCDC134-interacting proteins and comprehensively identify RNA-binding proteins. The results of ChIRP-MS (Supplementary Fig. 1D and E) and silver staining (Fig. 2D) showed that circCCDC134 cooperated with multiple proteins, including ALKBH5 and YTHDF2. Previous studies demonstrated that a-ketoglutarate-dependent dioxygenase AlkB homologue 5 (ALKBH5) (a demethylase) can remove m6A methylation from its target RNAs and lead to lower levels of m6A [18]; the reader protein YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) can selectively bind m6A-modified RNAs, recruit them to mRNA decay sites and then control target RNA stability [19]. To gain insight into the functions of circCCDC134-binding proteins, we implemented Protein–Protein Interaction Networks (PPI) and Gene Ontology (GO) based on mass spectrometry data. The PPI (Supplementary Fig. 1 F) and GO (Fig. 2E) results revealed that ALKBH5 and YTHDF2 mediated m6A modification, which could affect RNA stability. Therefore, we propose that circCCDC134 stability in CC is tuned by ALKBH5-mediated m6A modification.

![Fig. 2](image-url)
in a YTHDF2-dependent manner, increasing its expression. To further identify the ALKBH5 protein and YTHDF2 protein interacting with circCCDC134, we performed circRNA pull-down and RIP assays. The results of the circCCDC134 pull-down assay showed that the ALKBH5 protein and YTHDF2 protein could bind circCCDC134-MS2 (Fig. 2F and G). We performed RIP assays using anti-ALKBH5 or anti-YTHDF2 antibodies, and the results demonstrated that both ALKBH5 and YTHDF2 could interact with circCCDC134 (Fig. 2H and I). In order to quantify m6A levels of circCCDC134, m6A RNA immunoprecipitation (MeRIP) was performed. Gene-specific m6A qPCR to detect the m6A methylation status of circCCDC134 was performed and the results indicated that an reduction of m6A methylation in the ALKBH5 overexpression group of SiHA (Supplementary 1G) and ME180 (Supplementary 1H) cell lines. Next, we further confirmed the effect of ALKBH5 expression on circCCDC134 expression. We further analysed the correlation between ALKBH5 and circCCDC134 expression in CC. The qPCR and IHC results showed that the expression of ALKBH5 was low in CC (Fig. 2J and K), and patients with high ALKBH5 expression had much longer overall survival (Supplementary Fig. 1I). Next, circCCDC134 expression was significantly negatively correlated with survival (Supplementary Fig. 1I). Next, we further analysed the correlation between ALKBH5 and circCCDC134 expression in CC. The qPCR and IHC results showed that the expression of ALKBH5 was low in CC (Fig. 2J and K), and patients with high ALKBH5 expression had much longer overall survival (Supplementary Fig. 1I). Next, circCCDC134 expression was significantly negatively correlated with ALKBH5 expression in CC (Fig. 2L) based on the qPCR results. Moreover, the qRT–PCR and actinomycin D assays showed that the expression (Fig. 2M) and stability (Fig. 2N) of circCCDC134 were decreased with the overexpression of ALKBH5. Taken together, our data suggest that the ALKBH5-mediating m6A methylation of circCCDC134 is responsible for circCCDC134 upregulation by increasing its RNA stability via YTHDF2.

**circCCDC134 facilitates CC cell proliferation and metastasis in vitro and in vivo**

To gain insight into the function of circCCDC134, we characterized the oncogenic phenotypes in ME180 and SiHA cells with circCCDC134 silencing (Si-circCCDC134-1 and Si-circCCDC134-2) and HCC94 cells with circCCDC134 overexpression (EX-circCCDC134). The qPCR results showed that Si-circCCDC134-1 and Si-circCCDC134-2 could significantly inhibit circCCDC134 expression in CC cells (ME180 and SiHA cells) (Fig. 3A), and we chose Si-circCCDC134-1 and Si-circCCDC134-2 for the cell function experiments. We investigated the role of circCCDC134 in the proliferation of CC cells by a colony formation assay. To assess the influence of circCCDC134 on cell migration and invasion, Transwell assays were used to detect the cell migration and invasion capacity. The colony formation and Transwell assays revealed that the knockdown of circCCDC134 impaired the proliferation (Fig. 3B), migration (Fig. 3D), and invasion (Fig. 3E) of CC cells. Additionally, the overexpression of circCCDC134 significantly promoted CC cell proliferation (Fig. 3C), migration and invasion (Fig. 3F).

To further evaluate the effect of circCCDC134 on CC tumour growth and metastasis in vivo, we established xenograft growth and lung metastasis models. Notably, the xenografts (Fig. 3G) formed by ME180 cells bearing sh-circCCDC134 exhibited significantly slower growth rates (Fig. 3H) and lower tumour weights (Fig. 3I) than the scrambled controls. Furthermore, the volumes of the metastatic nodes in the lung in the circCCDC134 knockdown group were apparently smaller than those in the control group (Fig. 3J), and the number of metastatic nodes was significantly decreased in the circCCDC134 silencing group (Fig. 3K). Taken together, these findings suggest that circCCDC134 acts as an oncogene in CC metastasis by promoting cellular proliferation, migration and invasion.

**circCCDC134 dysregulation contributes to the abnormal expression of genes in CC**

To clarify the abnormal expression of genes related to CC metastasis and circCCDC134 disorder, mRNA-seq of CC (Fig. 4A), mRNA-seq of metastasis tissues (Fig. 4B) and mRNA-seq of si-circCCDC134/ME180 cells (ME180 cells transfected with si-circCCDC134-1) (Fig. 4C and D) were carried out. Furthermore, we implemented Kyoto Encyclopedia of Genes and Genomes (KEGG) (Fig. 4E) and gene set enrichment analysis (GSEA) (Fig. 4F and G) based on the si-circCCDC134 mRNA-seq data. The results revealed that the upregulated circCCDC134 expression was closely associated with the TNF signalling pathway. It has been acknowledged that the TNF signalling pathway [20] and epithelial-mesenchymal transition (EMT) [21] contribute to the metastatic progression of CC. To identify potential TNF and EMT mRNAs regulated by circCCDC134, we analysed the mRNA-seq data of CC tissues, metastatic tissues and the si-circCCDC134 group. Regarding TNF-related genes, by combining the TNF signalling pathway in the si-circCCDC134, CC and metastasis mRNA-seq data results, 5 genes were found, including SIK1, IER2, EFNA1, KLF2 and PER1 (Fig. 4H and I). Regarding EMT-related genes, 200 EMT-related genes were downloaded from the Molecular Signature database v7.1 (http://www.broad.mit.edu/gsea/msigdb/) [22]. By combining the EMT-related gene data, si-circCCDC134 mRNA-seq data, CC mRNA-seq data and metastasis mRNA-seq data, 4 genes were found, including DCN, PCOLCE, PMP22 and COL5A3 (Fig. 4I and J). Next, we explored the expression and survival analysis of these genes in CC based on TCGA databases, and the analysis revealed that EFNA1, KLF2, PER1 and COL5A3 expression was closely associated with CC overall
survival (Supplementary Fig. 2). In addition, the qRT–PCR analysis confirmed that the expression of EFNA1 was decreased in ME180 and SiHA cells and increased in HCC94 cells that were induced by circCCDC134. Regarding KLF2, PER1 and COL5A3, their expression was increased in ME180 and SiHA cells and decreased in HCC94 cells induced by circCCDC134 (Fig. 4K and L). These results demonstrate that circCCDC134 dysregulation contributes to the abnormal expression of TNF-related mRNAs and EMT-related mRNAs.

circCCDC134 stimulates HIF1A transcription by recruiting p65 and acting as a miR-503-5p sponge

Many studies have demonstrated that circRNAs play regulatory roles by binding proteins and sponging miRNAs. In the above experiments, ChIRP-MS was performed to determine whether circCCDC134 could interact with binding proteins, and the results showed that circCCDC134 cooperated with multiple nuclear proteins. Among the binding proteins, we found that circCCDC134 could interact with p65, which is a very important transcription factor that promotes CC metastasis [23] and interacts with the TNF signalling pathway [24] and EMT [25]. We explored the possibility that circCCDC134 interacts with p65, and the secondary structure of circCCDC134 was assembled in Mfold (version 2.3) following the methods described by Du William W et al. [26]. The molecular simulation results supported that circCCDC134 could perfectly dock with p65 (Fig. 5A). The results of the circRNA pull-down (Fig. 5B) and RIP (Fig. 5C) assays demonstrated that p65 could interact with circCCDC134. The western blot results showed that there was no significant change in the p65 protein levels upon circCCDC134 knockdown, indicating
that circCCDC134 does not regulate the expression of the P65 protein (Fig. 5D). Furthermore, ChIP-seq and ChIP–qPCR assays were used to identify target genes regulated by p65. As shown in Fig. 5E and F, p65 binds the upstream 5k region of 7.34% of genes that contain the gene promoter region based on the ChIP-seq results. Furthermore, AnimalTFDB 3.0, which is a comprehensive resource for the annotation and prediction of animal transcription factors, was used to analyse the key target genes of p65 [27]. By combining AnimalTFDB 3.0 data of p65, si-circCCDC134 mRNA-seq data, CC mRNA-seq data and P65 ChIP-seq data, HIF1A was found (Fig. 5G and H). We tested whether circCCDC134 regulates HIF1A transcription by enhancing p65, and the results were as follows: 1. p65 was enriched in the region −1200 to −400 bp from the transcription start site of the HIF1A promoter (Fig. 5I); 2. p65 enrichment at −1200 to −400 bp from the transcription start site of the HIF1A promoter was reduced after interference with p65 and circCCDC134 expression (Fig. 5J and K). Moreover, the qPCR results showed that the expression of HIF1A was rescued by transfection with p65 and si-circCCDC134 (Fig. 5L). Immunohistochemistry showed that the expression of HIF1A was positively correlated with the expression of circCCDC134 in the xenograft growth and lung metastasis models (Fig. 5M and N). These results suggest that circCCDC134 interacts with p65 to enhance HIF1A transcription.

Another key role of circRNAs is to sponge miRNAs and regulate downstream genes. To explore the miRNAs that could be sponged by circCCDC134, miRNA-seq data from CC tissues and metastatic tissues (Fig. 6A and B), the circBank database (http://www.circbank.cn/) and the circRNA database (https://circinteractome.nia.nih.gov/) were used. Among these data, only hsa-miR-503-5p was low in CC tissues and may be sponged by circCCDC134 (Fig. 6C). The qRT–PCR results revealed that the expression of miR-503-5p was low in the tumour
and metastatic tissues (Fig. 6D) and CC cells (Fig. 6E). The circRNA pull-down assays showed that miR-503-5p could specifically bind circCCDC134 (Fig. 6F). The RNA FISH assays revealed that circCCDC134 and miR-503-5p colocalized in the cytoplasm (Fig. 6G). The RIP assay also illustrated that circCCDC134 and miR-503-5p enrichment was increased in the Ago2 group compared that in the IgG group (Fig. 6H). We investigated the role of miR-503-5p in the proliferation of CC cells by a colony formation assay. To assess the influence of miR-503-5p on cell migration and invasion, Transwell assays were used to detect the cell migration and invasion capacity. The results showed that the transfection of the miR-503-5p mimic resulted in a decrease in proliferation, migration and invasion ability in ME180 cells, and the function of miR-503-5p was rescued by the reintroduction of circCCDC134 (Supplementary Fig. 3A). Furthermore, we sought to identify the specific target gene of miR-503-5p via the miRDB, miRTarBase and TargetScan databases. According to the miRDB, miRTarBase and TargetScan database analysis, 90 target genes were found (Supplementary Fig. 3B). Combined with the si-circCCDC134 mRNA-seq data, 14 target genes were analysed (Supplementary Fig. 3C).

Next, we explored the OS (overall survival) and RFS (relapse-free survival) associated with these 14 genes in CC based on TCGA databases. The analysis revealed that MYB (Supplementary Fig. 3D), CD2AP, KPNA3, NUFIP2, and TLL1 (Supplementary Figs. 4 and 5) expression was closely related to CC OS and RFS. Since MYB...
is known to be associated with CC migration and invasion [26], we chose MYB for further study. The luciferase reporter gene assay consists of cloning both the wild-type and mutated forms of the 3’UTR of the miRNA predicted mRNA target downstream of a firefly luciferase reporter. The luciferase reporter gene assay showed that luciferase activity was significantly inhibited in HEK-293 T cells that were cotransfected with the miR-503-5p mimic and wild-type luciferase reporter (circCCDC134-WT and MYB-WT) compared with those in the control group (Fig. 6I). Moreover, the qPCR results showed that the expression of MYB was rescued by transfection with sh-circCCDC134 and anti-miR-503-5p (Supplementary Fig. 3E) or transfection with circCCDC134 and miR-503-5p mimics. These findings indicate that circCCDC134 can act as a sponge for miR-503-5p to upregulate MYB in CC cells.

HIF1A as a downstream target of MYB

In previous studies, MYB was shown to be a very important transcription factor. To explore the downstream target of MYB, the JASPAR database (https://jaspar.genereg.net/) was used. Interestingly, HIF1A was an important MYB target gene (Fig. 7A). The motif analysis of the HIF1A transcription promoter site based on the high confidence of JASPAR is shown in Fig. 7B. The ChIP results showed that 1. MYB was enriched in the region −1200 to −200 bp from the transcription start site of the HIF1A promoter (Fig. 7C), and 2. MYB enrichment in −1200 to −200 bp from the transcription start site of the HIF1A promoter was reduced after MYB interference (Fig. 7D). Moreover, the qPCR results showed that the expression of HIF1A was rescued by transfection with MYB (Fig. 7E). These results demonstrate that MYB could stimulate HIF1A transcription.
Discussion

Metastasis of cervical cancer is often the main cause of treatment failure, and prognosis is still unsatisfactory [28]. Therefore, the identification of new therapeutic targets to improve the prognosis of patients with this disease is needed. Mounting evidence indicates that circRNAs are stable, conserved and diverse and often exhibit tissue- or developmental stage-specific expression. Due to their abundance and high stability, circRNAs are suitable as novel clinical molecular markers, thereby providing new insights into the treatment of diseases.

In this study, circRNA-Seq was used to analyse dysregulated circRNA expression in CC, and one of the new molecules that attracted our attention was circCCDC134. To detect the features of circCCDC134, the following experiments were performed: 1. Sanger sequencing was used to validate the existence and structure of circCCDC134; 2. qRT–PCR with oligo (dT) revealed that circCCDC134 contained no poly-A tail; 3. RNase R and actinomycin D showed that circCCDC134 was more stable than linear CCDC134; and 4. according to the FISH and RNA fractionation assays, the fluorescence signal of circCCDC134 was found in both the nucleus and cytoplasm. Additionally, we revealed upregulated expression of circCCDC134 in CC metastasis tissues and cells using qRT–PCR. Our data indicate that the expression of circCCDC134 was significantly high in CC tissues, especially in metastatic tissues. The FISH and RNA fractionation assays suggested that circCCDC134 could play a regulatory role in both the nucleus and the cytoplasm. Then, we focused on the mechanism underlying the association between circCCDC134 and CC metastasis in terms of dysregulated expression and regulatory mechanisms.

N6-methyladenosine is the most abundant and reversible internal modification in mRNAs and circRNAs;
recent studies have shown that m6A modification participates in circRNA expression. ALKBH5 is a member of the AlkB family and can remove m6A methylation from target RNAs and lead to lower m6A levels [16]. An increasing number of studies have found that ALKBH5 plays an important role in cancer progression. For example, ALKBH5 inhibits tumour growth and metastasis by abolishing the expression and activity of YAP in non-small cell lung cancer [29]. In the present study, the ChiRP-MS and RIP assays revealed that circCCDC134 cooperated with ALKBH5 and YTHDF2, and the qRT–PCR and actinomycin D assays showed that the expression and stability of circCCDC134 were decreased with ALKBH5 overexpression. These results show that circCCDC134 upregulation in CC was fine-tuned by ALKBH5-mediated m6A modification, which enhanced its stability in a YTHDF2-dependent manner. This type of m6A modification has been reported in previous studies investigating CC [30] and circular RNA expression in hepatocellular carcinoma [31], and our findings are consistent with these studies. Here, we first report that circCCDC134 is dominated by ALKBH5-mediated demethylation, followed by recognition and destabilization by YTHDF2, which is the mechanism by which circCCDC134 is dysregulated in CC metastasis. Our data provide novel evidence of circCCDC134 degradation in CC metastasis.

Recent studies have revealed that circRNAs can interact with RBPs and function as miRNA sponges to promote cancer metastasis. For instance, hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p [32]. In our previous study, circACTN4 promoted intrahepatic cholangiocarcinoma proliferation by metastasis as acting by a molecular sponge of miR-424-5p and interacting with YBX1 to transcriptionally activate FZD7. In this study, we demonstrate that circCCDC134 exerts its function not only through a ceRNA mechanism but also by recruiting p65, ultimately stimulating HIF1A transcription and facilitating CC growth and metastasis. The functional analyses validated the role of circCCDC134 in promoting the proliferation and metastasis of CC cells both in vivo and in vitro. To explore the regulatory mechanism of circCCDC134, ChiRP-MS assays, RIP assays, miRNA-seq/mRNA-seq of CC tissues and metastatic tissues, mRNA-seq of ME180 cells with si-circCCDC134, ChIP-seq and ChiP–qPCR assays were applied. The results revealed that circCCDC134 recruited p65 to the nucleus and acted as a miR-503-5p sponge to regulate the expression of MYB in the cytoplasm, ultimately stimulating HIF1A transcription and facilitating CC growth and metastasis. Evidence indicates that a high expression of HIF1A is associated with a worse 5-year overall survival rate in cervical cancer [33], which is consistent with the findings of the current study. Our results confirmed that circCCDC134 plays a crucial role in CC metastasis and progression by interacting with p65 and regulating the expression of the miR-503-5p target gene MYB. Interestingly, we found that HIF1A was an important target gene for both p65 and MYB. These findings indicate that circCCDC134 plays a key role in enhancing HIF1A transcription.

Conclusion

Our study was not free of limitations. First our results need to be validated in larger CC patient cohorts in terms of the overall survival prediction of circCCDC134. Second, we focused only on the roles of circCCDC134 in tumour proliferation and metastasis. More detailed studies are necessary to explore the impact of circCCDC134 on other malignant biological behaviours of CC cells, including angiogenesis and immune escape. Therefore, these unresolved limitations need to be addressed in future studies.

In summary, our findings highlight the attractive value of m6A demethylases in the expression of circCCDC134 and the key role of circCCDC134 in enhancing HIF1A transcription in the cytoplasm and nucleus. These findings shed light on novel molecular mechanisms and provide new insight into developing effective therapeutic strategies for CC metastasis.

Abbreviations

CC: Cervical cancer; circRNAs: Circular RNAs; m6A: N6-methyladenosine; ChirP-MS: CircRNA pull-down and mass spectrometry; Chip-seq: Chromatin immunoprecipitation-seq; RIP: RNA binding protein immunoprecipitation; miRNA: MicroRNA; RBP: RNA-binding protein; TRAP: Tagged RNA affinity purification; ALKBH5: α-ketoglutarate-dependent dioxygenase AlkB homologue 5; YTHDF2: YTH N6-methyladenosine RNA binding protein 2; PPI: Protein-protein interaction networks; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; GSEA: Gene set enrichment analysis; EMT: Epithelial-mesenchymal transition; OS: Overall survival; RFS: Relapse free survival.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13046-022-02462-7.

Additional file 1: Supplementary Table 1. Information concerning the clinical samples.

Additional file 2: Supplementary Table 2. Sequence information.

Additional file 3: Supplementary Fig. 1. (A and B): Melting curve and separation curve display the primers for circCCDC134 designed for the qRT–PCR experiments. (C): RNA fractionation assays showed that circCCDC134 was expressed in both the nucleus and cytoplasm of SiHA cells. (D and E): The mass spectrometry results of circCCDC134-binding proteins. (F): PPI analysis based on mass spectrometry data revealed that the ALKBH5 and YTHDF2 proteins could bind circCCDC134-M52. Gene-specific m6A qPCR to detect the m6A methylation status of circCCDC134 was performed and the results indicated that an reduction of m6A methylation in the ALKBH5 overexpression group of (Q): SiHA and (H): ME180 cell
The data used or analysed during the current study are available from the [source](http://example.com). The RFS of 14 genes in CC based on TCGA databases. (A): Patients with high ANK3 expression had a much longer OS in CC. (B-G): Patients with low ANLN, CD2AP, KPNA3, TSC22D2, TMEM245 and ZNF449 expression is not correlated with patient survival in CC.

Additional file 4: Supplementary Fig. 3. (A): Transfection of the miR-503-5p mimic resulted in a decrease in proliferation, migration and invasion ability in ME180 cells, and the function of miR-503-5p was rescued by the reintroduction of circCCDC134. (B): According to the miRDB, miRTarBase and TargetScan database analysis, 90 target genes were found. (C): Combined with the si-circCCDC134 mRNA-seq data, 14 target genes were analysed. (D): MYB was found to be the key target gene of miR-503-5p and was closely related to CC OS and RFS. (E): The qPCR results showed that the expression of MYB was rescued by transfection with sh-circCCDC134 and anti-miR-503-5p or transfection with circCCDC134 and miR-503-5p mimics.

Additional file 5: Supplementary Fig. 4. The survival analysis of 14 genes in CC based on TCGA databases. (A): Patients with high ANK3 expression had a much longer OS in CC. (B-G): Patients with low ANLN, CD2AP, KPNIA3, NUP163, SEC24A or TLL1 expression had a better OS in CC. (H-M): OS analysis revealed that MYB CDK17, CCND2, ZBTB34, TSC22D2, TMEM245 and ZNF449 expression is not correlated with patient survival in CC.

Additional file 7: Supplementary Fig. 5. The RFS of 14 genes in CC based on TCGA databases. (A): Patients with high ANK3 expression had a much longer RFS in CC. (B-G): Patients with low ANLN, CD2AP, KPNIA3, NUP163, SEC24A or TLL1 expression had a better RFS in CC. (H-M): The RFS analysis revealed that MYB CDK17, CCND2, ZBTB34, TSC22D2, TMEM245 and ZNF449 expression is not correlated with RFS in CC.

Acknowledgements

We thank the TCGA, AnimalTFDB 3.0, circBank, circRNA, miRDB, miRTarBase, TargetScan and JASPAR databases for the availability of the data.

Authors’ contributions

LYW conceived and designed the study. LL performed the experiments. YSZ and JL analysed the data and drafted the manuscript. JZ collected the CC samples and clinical information. All authors read and approved the final manuscript.

Funding

This work was financially supported by grants from the National Natural Science Foundation (No. 82173334 and No. 81972450) to Lingying Wu.

Availability of data and materials

The data used or analysed during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by the Ethics Committee of the Cancer Hospital of the Chinese Academy of Medical Sciences (NCC2021A002). Informed consent was obtained from all participants in the study.

Consent for publication

Not Applicable.

Competing interests

The authors have no conflicts of interest to declare.

Received: 25 April 2022 Accepted: 9 August 2022 Published online: 26 August 2022

References

1. Sun T, Sun C, Li G, Guo Z, Zhang L, Li J, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
2. Memczak S, Jens M, Elefsinioti A, Toril F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–8.
3. Yin Y, Long J, He Q, Li Y, Liao Y, He P, et al. Emerging roles of circular RNA in formation and progression of cancer. J Cancer. 2019;10(21):5015–21.
4. Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21(8):475–90.
5. Li J, Sun D, Pu W, Wang J, Peng Y. Circular RNAs in Cancer: Biogenesis, Function, and Clinical Significance. Trends Cancer. 2020;6(4):319–36.
6. Zhi Q, Wan D, Ren R, Xu Z, Guo X, Han Y, et al. Circular RNA profiling identifies circ102049 as a key regulator of colorectal liver metastasis. Mol Oncol. 2021;15(2):623–41.
7. Hu QZ, Zhou SL, Li J, Zhou ZJ, Wang PC, Xin HY, et al. Circular RNA Sequencing Identifies CircASAP1 as a Key Regulator in Hepatocellular Carcinoma Metastasis. Hepatology. 2020;72(3):906–22.
8. Wang L, Tong X, Zhou Z, Wang S, Lei Z, Zhang J, et al. Circular RNA has_circ_0008305 (circPVT2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer. Mol Cancer. 2018;17(1):140.
9. Chen Y, Lin Y, Shu Y, He J, Gao W. Interaction between N6-methyladenosine (m6A) modification and noncoding RNAs in cancer. Mol Cancer. 2020;19(1):94.
10. Lan Q, Liu PY, Haase J, Bell JL, Huttelmaier S, Liu T. The Critical Role of RNA N6-Methyladenosine Modification in Cancer. Cancer Res. 2019;79(7):1285–92.
11. Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N6-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018;28(5):507–17.
12. Yang Y, Fan X, Mao M, Song X, Wu P, Zhang Y, et al. Extensive translation of circular RNAs driven by N6-methyladenosine. Cell Res. 2017;27(5):626–41.
13. Chen RX, Chen X, Xia LP, Zhang JX, Pan ZZ, Ma XD, et al. N6-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMG2 to promote colorectal liver metastasis. Nat Commun. 2019;10(1):4695.
14. Liu H, Lan T, Li H, Xu L, Chen X, Liao H, et al. Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HtrA. THERANOSTICS. 2021;11(3):1396–411.
15. Liang L, Gao C, Li Y, Sun M, Xu J, Li H, et al. miR-125a-3p/FUT5/FUT6 axis mediates colorectal cancer cell proliferation, migration, invasion and pathological angiogenesis via PI3K-Akt pathway. Cell Death Dis. 2018;9(8):e2968.
16. Liang L, Xu J, Wang M, Xu G, Zhang N, Wang G, et al. LncRNA HCPS promotes follicular thyroid carcinoma progression via miRNAs sponge. Cell Death Dis. 2018;9(3):372.
17. Chen Q, Wang H, Li Z, Li F, Liang L, Zou Y, et al. Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate Fzd7 transcription. J Hepatol. 2022;76(1):135–47.
18. Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49(1):18–29.
19. Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117–20.
20. Park Y, Pang K, Park J, Hong E, Lee J, Ooshima A, et al. Destabilization of TRAF6 by DRAK1 Suppresses Tumor Growth and Metastasis in Cervical Cancer Cells. Cancer Res. 2020;80(12):2537–49.
21. Li Q, Zhou ZW, Duan W, Qian CY, Wang SN, Deng MS, et al. Inhibiting the redox function of APE1 suppresses cervical cancer metastasis via disengagement of ZEB1 from E-cadherin in EMT. J Exp Clin Cancer Res. 2021;40(1):220.
22. Li D, Lin X, Chen B, Ma Z, Zeng Y, Wang H. Identification and Validation of EMT-Related lncRNA Prognostic Signature for Colorectal Cancer. Front Genet. 2021;12.
23. Ali A, Kim SH, Kim MJ, Choi MY, Kang SS, Cho GJ, et al. O-GlcNAcylation of NF-kB Promotes Lung Metastasis of Cervical Cancer Cells via Upregulation of CXCR4 Expression. Mol Cells. 2017;40(7):746–84.
24. Wu J, Zhao Y, Park YK, Lee JY, Gao L, Zhao J, et al. Loss of PDK4 switches the hepatic NF-κB/TNF pathway from pro-survival to pro-apoptosis. Hepatology. 2018;68(3):1111–24.
25. Inoue H, Hashimura M, Akita M, Chiba R, Saegusa M. Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma. Mol Cancer. 2017;16(1):37.
26. Du WW, Fang L, Yang W, Wu N, Awan FM, Yang Z, et al. Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity. Cell Death Differ. 2017;24(2):357–70.
27. Hu H, Miao YR, Jia LH, Yu QY, Zhang Q, Guo AY. AnimalTFDB 3.0: a comprehensive resource for annotation and prediction of animal transcription factors. Nucleic Acids Res. 2019;47(D1):D33-8.
28. Uyar D, Rader J. Genomics of cervical cancer and the role of human papillomavirus pathobiology. Clin Chem. 2014;60(1):144–6.
29. Jin D, Guo J, Wu Y, Yang L, Wang X, Du J, et al. m6A demethylase ALKBHS inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC. Mol Cancer. 2020;19(1):40.
30. Wang X, Zhang J, Wang Y. Long noncoding RNA GASS-AS1 suppresses growth and metastasis of cervical cancer by increasing GASS stability. Am J Transl Res. 2019;11(8):4909–21.
31. Chen Y, Ling Z, Cai X, Xu Y, Lv Z, Man D, et al. Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma. Cancer Res. 2022;82(4):599–614.
32. Yu YZ, Lv DJ, Wang C, Song XL, Xie T, Wang T, et al. Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-Sp. Mol Cancer. 2022;21(1):12.
33. Kim BW, Cho H, Chung JT, Conway C, Ylaya K, Kim JH, et al. Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry. J Transl Med. 2013;11:185.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.